Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 56Ovarian Neoplasms 35Carcinoma, Hepatocellular 35Neoplasms 25Fallopian Tube Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Endometrial Neoplasms 13Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Colonic Neoplasms 9Lung Neoplasms 8Uterine Cervical Neoplasms 7Liver Neoplasms 7Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

Tranexamic Acid 1Solutions 1Sodium Chloride 1Saline Solution 1N(4)-oleylcytosine arabinoside 1Injections, Intravenous 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhage × Bevacizumab × 90 days × Clear all
NCT07527832 2026-06-03

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Pfizer

Completed
1,000 enrolled
Gastrointestinal

Hemorrhage, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡